{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:52:24Z","timestamp":1781826744414,"version":"3.54.5"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T00:00:00Z","timestamp":1781740800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"DOI":"10.1007\/s11739-026-04438-3","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T10:25:57Z","timestamp":1781778357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of emerging antiobesity and antidiabetic drugs on atherosclerosis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9775-9715","authenticated-orcid":false,"given":"Giuseppe","family":"Armentaro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Severini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Alberto","family":"Pastura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosangela","family":"Scarcelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velia","family":"Cassano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Sciacqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,18]]},"reference":[{"issue":"10397","key":"4438_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"GBD 2021 Diabetes Collaborators","year":"2021","unstructured":"GBD 2021 Diabetes Collaborators (2021) Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 402(10397):203\u2013234. https:\/\/doi.org\/10.1016\/S0140-6736(23)01301-6","journal-title":"Lancet"},{"key":"4438_CR2","doi-asserted-by":"publisher","first-page":"1095753","DOI":"10.3389\/fendo.2023.1095753","volume":"14","author":"I Zaffina","year":"2023","unstructured":"Zaffina I, Pelle MC, Armentaro G, Giofr\u00e8 F, Cassano V, Sciacqua A, Arturi F (2023) Effect of dual glucose-dependent insulinotropic peptide\/glucagon-like peptide-1 receptor agonist on weight loss in subjects with obesity. Front Endocrinol (Lausanne) 14:1095753. https:\/\/doi.org\/10.3389\/fendo.2023.1095753","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"4438_CR3","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1161\/CIRCRESAHA.116.308999","volume":"118","author":"PE Scherer","year":"2016","unstructured":"Scherer PE, Hill JA (2016) Obesity, diabetes, and cardiovascular diseases: a compendium. Circ Res 118(11):1703\u20131705. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.308999","journal-title":"Circ Res"},{"issue":"6","key":"4438_CR4","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/nu14061299","volume":"14","author":"V Cassano","year":"2022","unstructured":"Cassano V, Miceli S, Armentaro G et al (2022) Oxidative stress and left ventricular performance in patients with different glycometabolic phenotypes. Nutrients 14(6):1299. https:\/\/doi.org\/10.3390\/nu14061299","journal-title":"Nutrients"},{"issue":"4","key":"4438_CR5","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.mcna.2004.04.008","volume":"88","author":"RM Krauss","year":"2004","unstructured":"Krauss RM, Siri PW (2004) Dyslipidemia in type 2 diabetes. Med Clin North Am 88(4):897\u2013909. https:\/\/doi.org\/10.1016\/j.mcna.2004.04.004","journal-title":"Med Clin North Am"},{"issue":"1","key":"4438_CR6","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1161\/01.HYP.0000151325.83008.b4","volume":"45","author":"K Rahmouni","year":"2005","unstructured":"Rahmouni K, Correia MLG, Haynes WG, Mark AL (2005) Obesity-associated hypertension: new insights into mechanisms. Hypertension 45(1):9\u201314. https:\/\/doi.org\/10.1161\/01.HYP.0000151325.83008.b4","journal-title":"Hypertension"},{"issue":"2","key":"4438_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.ecl.2005.12.001","volume":"33","author":"A Natali","year":"2006","unstructured":"Natali A, Ferrannini E (2004) Hypertension, insulin resistance, and the metabolic syndrome. Endocrinol Metab Clin North Am  33(2):417\u2013429. https:\/\/doi.org\/10.1016\/j.ecl.2004.03.007","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"4438_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12933-024-02177-3","volume":"23","author":"V Cassano","year":"2024","unstructured":"Cassano V, Armentaro G, Iembo D et al (2024) Mean platelet volume (MPV) as new marker of diabetic macrovascular complications in patients with different glucose homeostasis: platelets in cardiovascular risk. Cardiovasc Diabetol 23(1):89. https:\/\/doi.org\/10.1186\/s12933-024-02177-3","journal-title":"Cardiovasc Diabetol"},{"key":"4438_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.695961","volume":"12","author":"A Sciacqua","year":"2021","unstructured":"Sciacqua A, Andreozzi F, Succurro E et al (2021) Impaired clinical efficacy of aspirin in hypoalbuminemic patients with diabetes mellitus. Front Pharmacol 12:695961. https:\/\/doi.org\/10.3389\/fphar.2021.695961","journal-title":"Front Pharmacol"},{"key":"4438_CR10","doi-asserted-by":"publisher","unstructured":"Manrique C, Lastra G, Gardner M, Sowers JR (2009) The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am  93(3):569\u2013582. https:\/\/doi.org\/10.1016\/j.mcna.2009.02.014","DOI":"10.1016\/j.mcna.2009.02.014"},{"issue":"9","key":"4438_CR11","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"P Libby","year":"2002","unstructured":"Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105(9):1135\u20131143. https:\/\/doi.org\/10.1161\/hc0902.104353","journal-title":"Circulation"},{"issue":"16","key":"4438_CR12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352(16):1685\u20131695. https:\/\/doi.org\/10.1056\/NEJMra043430","journal-title":"N Engl J Med"},{"issue":"Suppl 6A","key":"4438_CR13","doi-asserted-by":"publisher","first-page":"9S","DOI":"10.1016\/j.amjmed.2004.02.006","volume":"116","author":"P Libby","year":"2004","unstructured":"Libby P, Ridker PM (2004) Inflammation and atherosclerosis: role of C-reactive protein in risk assessment. Am J Med 116(Suppl 6A):9S-16S. https:\/\/doi.org\/10.1016\/j.amjmed.2004.02.006","journal-title":"Am J Med"},{"key":"4438_CR14","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK (2024) Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne) 15:1431292. https:\/\/doi.org\/10.3389\/fendo.2024.1431292","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"24","key":"4438_CR15","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","volume":"146","author":"N Marx","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N (2022) GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation 146(24):1882\u20131894. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.122.059595","journal-title":"Circulation"},{"issue":"Suppl 1","key":"4438_CR16","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.2337\/dc25-S009","volume":"48","author":"NA ElSayed","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed NA, McCoy RG et al (2025) 9. Pharmacologic approaches to glycemic treatment: standards of Care in Diabetes\u20142025. Diabetes Care 48(Suppl 1):S181\u2013S206. https:\/\/doi.org\/10.2337\/dc25-S009","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"4438_CR17","doi-asserted-by":"publisher","first-page":"S207","DOI":"10.2337\/dc25-S010","volume":"48","author":"NA ElSayed","year":"2025","unstructured":"American Diabetes Association Professional Practice Committee, ElSayed NA, McCoy RG et al (2025) 10. Cardiovascular disease and risk management: standards of Care in Diabetes\u20142025. Diabetes Care 48(Suppl 1):S207\u2013S238","journal-title":"Diabetes Care"},{"issue":"39","key":"4438_CR18","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K et al (2023) 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J 44(39):4043\u20134140. https:\/\/doi.org\/10.1093\/eurheartj\/ehad192","journal-title":"Eur Heart J"},{"issue":"36","key":"4438_CR19","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","volume":"45","author":"C Vrints","year":"2024","unstructured":"Vrints C, Andreotti F, Koskinas KC et al (2024) 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J 45(36):3415\u20133537. https:\/\/doi.org\/10.1093\/eurheartj\/ehae177","journal-title":"Eur Heart J"},{"issue":"5","key":"4438_CR20","doi-asserted-by":"publisher","first-page":"H1159","DOI":"10.1152\/ajpheart.00574.2023","volume":"326","author":"B Park","year":"2024","unstructured":"Park B, Bakbak E, Teoh H, Krishnaraj A, Dennis F, Quan A et al (2024) GLP-1 receptor agonists and atherosclerosis protection: the vascular endothelium takes center stage. Am J Physiol Heart Circ Physiol 326(5):H1159\u2013H1176. https:\/\/doi.org\/10.1152\/ajpheart.00574.2023","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"4438_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K et al (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375(4):311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"issue":"19","key":"4438_CR22","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A et al (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 375(19):1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"issue":"9","key":"4438_CR23","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M et al (2019) Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 381(9):841\u2013851","journal-title":"N Engl J Med"},{"issue":"10193","key":"4438_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394(10193):121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet"},{"issue":"20","key":"4438_CR25","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","volume":"392","author":"DK McGuire","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL et al (2025) Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med 392(20):2001\u20132012. https:\/\/doi.org\/10.1056\/NEJMoa2501006","journal-title":"N Engl J Med"},{"issue":"6","key":"4438_CR26","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med 385(6):503\u2013515. https:\/\/doi.org\/10.1056\/NEJMoa2107519","journal-title":"N Engl J Med"},{"issue":"24","key":"4438_CR27","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Pavo I, Bhatt DL et al (2025) Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes. N Engl J Med 393(24):2409\u20132420. https:\/\/doi.org\/10.1056\/NEJMoa2505928","journal-title":"N Engl J Med"},{"issue":"5","key":"4438_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2025.101740","volume":"4","author":"SS Dani","year":"2025","unstructured":"Dani SS, Makwana B, Khadke S et al (2025) An observational study of cardiovascular outcomes of tirzepatide vs glucagon-like peptide-1 receptor agonists. JACC Adv 4(5):101740. https:\/\/doi.org\/10.1016\/j.jacadv.2025.101740","journal-title":"JACC Adv"},{"issue":"3","key":"4438_CR29","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/dom.13899","volume":"22","author":"I Avgerinos","year":"2020","unstructured":"Avgerinos I, Michailidis T, Liakos A, Karagiannis T, Matthews DR, Tsapas A et al (2020) Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22(3):335\u2013345. https:\/\/doi.org\/10.1111\/dom.13899","journal-title":"Diabetes Obes Metab"},{"key":"4438_CR30","doi-asserted-by":"publisher","first-page":"1731127","DOI":"10.3389\/fcvm.2025.1731127","volume":"12","author":"S Tan","year":"2025","unstructured":"Tan S, Yin Y, Lu J (2025) Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Front Cardiovasc Med 12:1731127. https:\/\/doi.org\/10.3389\/fcvm.2025.1731127","journal-title":"Front Cardiovasc Med"},{"key":"4438_CR31","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","volume":"30","author":"TD M\u00fcller","year":"2019","unstructured":"M\u00fcller TD, Finan B, Bloom SR et al (2019) Glucagon-like peptide 1 (GLP-1). Mol Metab 30:72\u2013130. https:\/\/doi.org\/10.1016\/j.molmet.2019.09.010","journal-title":"Mol Metab"},{"issue":"10","key":"4438_CR32","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1172\/JCI75276","volume":"124","author":"A Secher","year":"2014","unstructured":"Secher A, Jelsing J, Baquero AF et al (2014) The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss. J Clin Invest 124(10):4473\u20134488. https:\/\/doi.org\/10.1172\/JCI75276","journal-title":"J Clin Invest"},{"issue":"6","key":"4438_CR33","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","volume":"38","author":"J Van Can","year":"2014","unstructured":"Van Can J, Sloth B, Jensen CB et al (2014) Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond) 38(6):784\u2013793. https:\/\/doi.org\/10.1038\/ijo.2013.162","journal-title":"Int J Obes (Lond)"},{"key":"4438_CR34","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389:2221\u20132232","journal-title":"N Engl J Med"},{"key":"4438_CR35","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P et al (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391:109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"4438_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2025.133028","volume":"423","author":"V De Sio","year":"2025","unstructured":"De Sio V, Gragnano F, Capolongo A et al (2025) Eligibility for and practical implications of semaglutide in overweight and obese patients with acute coronary syndrome. Int J Cardiol 423:133028. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133028","journal-title":"Int J Cardiol"},{"issue":"3","key":"4438_CR37","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","volume":"28","author":"N Sattar","year":"2022","unstructured":"Sattar N, McGuire DK, Pavo I et al (2022) Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med 28(3):591\u2013598. https:\/\/doi.org\/10.1038\/s41591-022-01707-4","journal-title":"Nat Med"},{"issue":"10295","key":"4438_CR38","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","volume":"398","author":"J Rosenstock","year":"2021","unstructured":"Rosenstock J, Wysham C, Fr\u00edas JP et al (2021) Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet 398(10295):143\u2013155. https:\/\/doi.org\/10.1016\/S0140-6736(21)01324-6","journal-title":"Lancet"},{"key":"4438_CR39","doi-asserted-by":"publisher","DOI":"10.2337\/db21-78-lb","author":"B Ludvik","year":"2021","unstructured":"Ludvik B, Giorgino F, J\u00f3dar E, et al (2021) Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398(10300):583\u2013598. https:\/\/doi.org\/10.1016\/S0140-6736(21)01443-4","journal-title":"Lancet"},{"key":"4438_CR40","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","volume":"392","author":"M Packer","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM et al (2025) Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med 392:427\u2013437. https:\/\/doi.org\/10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"issue":"7","key":"4438_CR41","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41569-024-01115-w","volume":"22","author":"AW Khan","year":"2025","unstructured":"Khan AW, Jandeleit-Dahm KAM (2025) Atherosclerosis in diabetes mellitus: novel mechanisms and mechanism-based therapeutic approaches. Nat Rev Cardiol 22(7):482\u2013496. https:\/\/doi.org\/10.1038\/s41569-024-01115-w","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"4438_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bcpt.13054","volume":"123","author":"CA Pereira","year":"2018","unstructured":"Pereira CA, Carneiro FS, Matsumoto T, Tostes RC (2018) Bonus effects of antidiabetic drugs: possible beneficial effects on endothelial dysfunction, vascular inflammation and atherosclerosis. Basic Clin Pharmacol Toxicol 123(5):523\u2013538. https:\/\/doi.org\/10.1111\/bcpt.13054","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"Pt 1","key":"4438_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2025.147734","volume":"329","author":"HM Al-Kuraishy","year":"2025","unstructured":"Al-Kuraishy HM, Sulaiman GM, Mohammed HA et al (2025) The mechanistic role of tirzepatide in atherosclerosis: a review. Int J Biol Macromol 329(Pt 1):147734. https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.147734","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"4438_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-016-0334-0","volume":"15","author":"L Xu","year":"2016","unstructured":"Xu L, Wang YR, Li PC, Feng B (2016) Advanced glycation end products increase lipids accumulation in macrophages through upregulation of receptor of advanced glycation end products: increasing uptake, esterification and decreasing efflux of cholesterol. Lipids Health Dis 15(1):161. https:\/\/doi.org\/10.1186\/s12944-016-0334-0","journal-title":"Lipids Health Dis"},{"key":"4438_CR45","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ahj.2024.08.015","volume":"278","author":"H Hamidi","year":"2024","unstructured":"Hamidi H, Baghery M, Benzing T et al (2024) Effect of tirzepatide on the progression of coronary atherosclerosis using MDCT: rationale and design of the tirzepatide treatment on coronary atherosclerosis progression: the (T-Plaque) randomized-controlled trial design. Am Heart J 278:24\u201332. https:\/\/doi.org\/10.1016\/j.ahj.2024.08.015","journal-title":"Am Heart J"},{"issue":"6","key":"4438_CR46","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3390\/life14060690","volume":"14","author":"M Hachuna","year":"2024","unstructured":"Hachuna M, Basiak M, Kosowski M, Okopien B (2024) Effect of GLP-1RA treatment on adhesion molecules and monocyte chemoattractant protein-1 in diabetic patients with atherosclerosis. Life (Basel) 14(6):690. https:\/\/doi.org\/10.3390\/life14060690","journal-title":"Life (Basel)"},{"key":"4438_CR47","doi-asserted-by":"publisher","first-page":"10202","DOI":"10.1038\/srep10202","volume":"5","author":"X Song","year":"2015","unstructured":"Song X, Jia H, Jiang Y et al (2015) Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 diabetes mellitus: a meta-analysis. Sci Rep 5:10202. https:\/\/doi.org\/10.1038\/srep10202","journal-title":"Sci Rep"},{"issue":"23","key":"4438_CR48","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","volume":"151","author":"N Marx","year":"2025","unstructured":"Marx N, Deanfield JE, Mann JFE, Arechavaleta R, Bain SC, Bajaj HS et al (2025) Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial. Circulation 151(23):1639\u20131650. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.125.074545","journal-title":"Circulation"},{"issue":"1","key":"4438_CR49","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"P Libby","year":"2019","unstructured":"Libby P, Buring JE, Badimon L et al (2019) Atherosclerosis. Nat Rev Dis Primers 5(1):56. https:\/\/doi.org\/10.1038\/s41572-019-0106-z","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"4438_CR50","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12317","volume":"36","author":"W Garczorz","year":"2018","unstructured":"Garczorz W, Gallego-Colon E, Kosowska A, Knych-Ratuszny A, Wonniak M, Marcol W et al (2018) Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor a-mediated activation. Cardiovasc Ther 36(2):e12317. https:\/\/doi.org\/10.1111\/1755-5922.12317","journal-title":"Cardiovasc Ther"},{"issue":"1\u20132","key":"4438_CR51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mce.2010.04.022","volume":"325","author":"O Erdogdu","year":"2010","unstructured":"Erdogdu O, Nathanson D, Sj\u00f6holm A, Nystr\u00f6m T, Zhang Q (2010) Exendin-4 stimulates proliferation of human coronary artery endothelial cells through eNOS-PKA- and PI3K\/Akt-dependent pathways and requires GLP-1 receptor. Mol Cell Endocrinol 325(1\u20132):26\u201335. https:\/\/doi.org\/10.1016\/j.mce.2010.04.022","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"4438_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026586","volume":"12","author":"YX Zhu","year":"2023","unstructured":"Zhu YX, Li Y, Ma Y, Zhang X, Du X, Gao J et al (2023) Liraglutide accelerates ischemia-induced angiogenesis in a murine diabetic model. J Am Heart Assoc 12(4):e026586. https:\/\/doi.org\/10.1161\/JAHA.122.026586","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"4438_CR53","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1007\/s00125-017-4330-5","volume":"60","author":"\u00c1 Vin\u00fae","year":"2017","unstructured":"Vin\u00fae \u00c1, Navarro J, Herrero-Cervera A et al (2017) The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia 60(9):1801\u20131812. https:\/\/doi.org\/10.1007\/s00125-017-4330-5","journal-title":"Diabetologia"},{"issue":"11","key":"4438_CR54","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1007\/s00125-011-2294-3","volume":"54","author":"AE Hogan","year":"2011","unstructured":"Hogan AE, Tobin AM, Ahern T et al (2011) Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis. Diabetologia 54(11):2745\u20132754. https:\/\/doi.org\/10.1007\/s00125-011-2294-3","journal-title":"Diabetologia"},{"issue":"3","key":"4438_CR55","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1124\/jpet.119.258483","volume":"370","author":"R Bruen","year":"2019","unstructured":"Bruen R, Curley S, Kajani S et al (2019) Liraglutide attenuates preestablished atherosclerosis in apolipoprotein E-deficient mice via regulation of immune cell phenotypes and proinflammatory mediators. J Pharmacol Exp Ther 370(3):447\u2013458. https:\/\/doi.org\/10.1124\/jpet.119.258483","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"4438_CR56","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","volume":"3","author":"G Rakipovski","year":"2018","unstructured":"Rakipovski G, Rolin B, N\u00f8hr J et al (2018) The GLP-1 analogs liraglutide and semaglutide reduce atherosclerosis in ApoE-\/- and LDLr-\/- mice by a mechanism that includes inflammatory pathways. JACC Basic Transl Sci 3(6):844\u2013857. https:\/\/doi.org\/10.1016\/j.jacbts.2018.09.004","journal-title":"JACC Basic Transl Sci"},{"issue":"4","key":"4438_CR57","doi-asserted-by":"publisher","first-page":"975","DOI":"10.2337\/db08-1193","volume":"58","author":"MH Noyan-Ashraf","year":"2009","unstructured":"Noyan-Ashraf MH, Momen MA, Ban K et al (2009) GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 58(4):975\u2013983. https:\/\/doi.org\/10.2337\/db08-1193","journal-title":"Diabetes"},{"key":"4438_CR58","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-025-09991-4","author":"W Masson","year":"2025","unstructured":"Masson W, Lobo M, Nogueira JP et al (2025) Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-025-09991-4","journal-title":"Rev Endocr Metab Disord"},{"key":"4438_CR59","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.atherosclerosis.2022.04.002","volume":"352","author":"JK Jensen","year":"2022","unstructured":"Jensen JK, Binderup T, Grandjean CE, et al (2022)  Semaglutide reduces vascular inflammation investigated by PET in a rabbit model of advanced atherosclerosis. Atherosclerosis  352:88\u201395. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2022.03.032","journal-title":"Atherosclerosis"},{"issue":"1","key":"4438_CR60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/CIRCULATIONAHA.112.091215","volume":"127","author":"MH Noyan-Ashraf","year":"2013","unstructured":"Noyan-Ashraf MH, Shikatani EA, Schuiki I et al (2013) A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation 127(1):74\u201385. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.091215","journal-title":"Circulation"},{"key":"4438_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.172929","volume":"871","author":"SH Fan","year":"2020","unstructured":"Fan SH, Xiong QF, Wang L, Zhang LH, Shi YW. Glucagon-like peptide 1 treatment reverses vascular remodelling by downregulating matrix metalloproteinase 1 expression through inhibition of the ERK1\/2\/NF-\u03baB signalling pathway. Mol Cell Endocrinol. 2020 Dec 1;518:111005. https:\/\/doi.org\/10.1016\/j.mce.2020.111005","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4438_CR62","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bbrc.2010.12.131","volume":"405","author":"H Goto","year":"2011","unstructured":"Goto H, Nomiyama T, Mita T et al (2011) Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces intimal thickening after vascular injury. Biochem Biophys Res Commun 405(1):79\u201384. https:\/\/doi.org\/10.1016\/j.bbrc.2010.12.131","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"4438_CR63","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.7150\/thno.66456","volume":"12","author":"A Maiseyeu","year":"2022","unstructured":"Maiseyeu A, Di L, Ravodina A, Barajas-Espinosa A, Sakamoto A, Chaplin A et al (2022) Plaque-targeted, proteolysis-resistant, activatable and MRI-visible nano-GLP-1 receptor agonist targets smooth muscle cell differentiation in atherosclerosis. Theranostics 12(6):2741\u20132757. https:\/\/doi.org\/10.7150\/thno.66456","journal-title":"Theranostics"},{"key":"4438_CR64","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwaf257","author":"A Cesaro","year":"2025","unstructured":"Cesaro A, Pastori D, Acerbo V, Biccir\u00e8 FG, Golino M, Panico D et al (2025) Reduction of new onset of atrial fibrillation in patients treated with semaglutide: an updated systematic review and meta-regression analysis of randomized controlled trials. Eur J Prev Cardiol. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf257","journal-title":"Eur J Prev Cardiol"},{"issue":"4","key":"4438_CR65","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1111\/dom.14634","volume":"24","author":"PJ Raubenheimer","year":"2022","unstructured":"Raubenheimer PJ, Cushman WC, Avezum A et al (2022) Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: a post hoc analysis from the REWIND randomized trial. Diabetes Obes Metab 24(4):704\u2013712. https:\/\/doi.org\/10.1111\/dom.14634","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"4438_CR66","doi-asserted-by":"publisher","first-page":"462","DOI":"10.3390\/ph19030462","volume":"19","author":"M Xanthopoulou","year":"2026","unstructured":"Xanthopoulou M, Evangelidis P, Poulis D, Gavriilaki E, Kotsiou N, Antza C et al (2026) Glucagon-like peptide-1 receptor agonists and platelet function: potential benefits beyond glycemic control. Pharmaceuticals 19(3):462. https:\/\/doi.org\/10.3390\/ph19030462","journal-title":"Pharmaceuticals"},{"issue":"16","key":"4438_CR67","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13164674","volume":"13","author":"R Le","year":"2024","unstructured":"Le R, Nguyen MT, Allahwala MA, Psaltis JP, Marathe CS, Marathe JA et al (2024) Cardiovascular protective properties of GLP-1 receptor agonists: more than just diabetic and weight loss drugs. J Clin Med 13(16):4674. https:\/\/doi.org\/10.3390\/jcm13164674","journal-title":"J Clin Med"},{"issue":"5","key":"4438_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2022.108188","volume":"36","author":"J Loganathan","year":"2022","unstructured":"Loganathan J, Cohen AC, Kaloupis GM, Harris C, Chronopoulos A, James V et al (2022) A pilot clinical study to evaluate liraglutide-mediated anti-platelet activity in patients with type-2 diabetes (ELAID study). J Diabetes Complicat 36(5):108188. https:\/\/doi.org\/10.1016\/j.jdiacomp.2022.108188","journal-title":"J Diabetes Complicat"},{"issue":"7","key":"4438_CR69","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jacbts.2022.04.004","volume":"7","author":"KN Cahill","year":"2022","unstructured":"Cahill KN, Amin T, Boutaud O, Printz R, Newcomb DC, Foer D et al (2022) Glucagon-like peptide-1 receptor regulates thromboxane-induced human platelet activation. JACC: Basic Transl Sci 7(7):713\u2013715. https:\/\/doi.org\/10.1016\/j.jacbts.2022.04.004","journal-title":"JACC: Basic Transl Sci"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04438-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04438-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T23:07:14Z","timestamp":1781824034000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04438-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,18]]},"references-count":69,"alternative-id":["4438"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04438-3","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,18]]},"assertion":[{"value":"29 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}